GlassScriptPhysician profile
Linda Sullivan
NPI 1932425089
$2,994.91
in general payments reported to CMS, 2019-2025
27 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.58 · 2022: $241 · 2023: $631 · 2024: $1,475 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,704 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,704.04 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.15 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $291.71 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $278.53 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $250.09 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $233.47 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $225.80 | 2024-2025 | |
| Abbott Laboratories | $217.63 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $126.44 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.11 | 2022-2024 | Jardiance |
| Amgen INC. | $113.37 | 2023-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $112.65 | 2023-2025 | |
| Exact Sciences Corporation | $86.75 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $73.29 | 2024-2025 | Rexulti |
| Dexcom, INC. | $49.04 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.98 | 2024-2025 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $39.43 | 2023-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $30.93 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Currax Pharmaceuticals LLC | $29.07 | 2022-2023 | Contrave |
| Eisai INC. | $28.54 | 2024 | |
| Sumitomo Pharma America, INC. | $24.57 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $21.01 | 2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.65 | 2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $17.74 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $16.36 | 2022 | |
| Baxter Healthcare | $15.44 | 2022 | |
| Irhythm Technologies, INC. | $14.26 | 2023 | Zio Xt Patch |
| Hikma Pharmaceuticals USA | $13.90 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.